Natera (NTRA) Metrics: History & Chart

Natera, Inc.(NTRA)

Medical - Diagnostics & Research · Austin, TX

$410.35+1.88 (+0.46%)

Delayed quote: Oct 2, 2026, 4:00 PM EDT

About Natera, Inc.

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Austin, TX

6,138 employees

www.natera.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Steven Leonard Chapman

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-0.08%
30D Total Return	+27.34%
YTD Total Return	+78.30%
1Y Total Return	+152.75%
3Y Total Return	+823.06%
5Y Total Return	+263.44%
10Y Total Return	+3576.27%
15Y Total Return	N/A
20Y Total Return	N/A

2026	+78.30%
2025	+44.72%
2024	+152.71%
2023	+55.94%
2022	-56.99%
2021	-6.16%
2020

CAGR TTM	+152.91%
CAGR 3Y	+109.45%
CAGR 5Y	+29.45%
CAGR 10Y	+43.39%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

NTRA Valuation Metrics

NTRA Stock Price Metrics

NTRA Dividend Metrics

NTRA Growth Rate Metrics

NTRA Discounted Cash Flow Metrics

NTRA Returns By Period

NTRA Yearly Returns

NTRA Average Annual Returns By Period (CAGR)

NTRA Revenue Metrics

NTRA PE Ratio Metrics

NTRA PS Ratio Metrics

NTRA PB Ratio Metrics

NTRA Price to Free Cash Flow Ratio Metrics

NTRA Debt to Equity Ratio Metrics

NTRA PEG Ratio Metrics

NTRA FCF Yield

NTRA Earnings Yield

NTRA EBITDA Yield

NTRA OCF Yield

NTRA EV/EBIT Ratio Metrics

NTRA EV/EBITDA Ratio Metrics

NTRA EV/Assets Ratio Metrics

NTRA EV/Sales Ratio Metrics

NTRA Current Ratio Metrics

NTRA Quick Ratio Metrics

NTRA ROIC Metrics

NTRA Return on Assets Metrics

NTRA Return on Equity Metrics

NTRA Net Profit Margin Metrics

NTRA Gross Profit Margin Metrics

NTRA Tax Rate Metrics

PS Ratio	21.62
PS Ratio Avg TTM	14.00
PS Ratio Avg 3Y	11.81
Current VS TTM Avg	+54.45%
Current VS 3Y Avg	+83.05%
Current VS 5Y Avg	+113.16%

PB Ratio	32.13
PB Ratio Avg TTM	21.59
PB Ratio Avg 3Y	17.73
Current VS TTM Avg	+48.80%
Current VS 3Y Avg	+81.20%
Current VS 5Y Avg	+123.05%

PFCF Ratio	816.28
PFCF Ratio Avg TTM	320.46
PFCF Ratio Avg 3Y	289.54
Current VS TTM Avg	+154.72%
Current VS 3Y Avg	+181.92%
Current VS 5Y Avg	+181.92%

Debt/Equity Ratio	0.13
Debt/Equity Ratio Avg TTM	0.14
Debt/Equity Ratio Avg 3Y	0.35
Current VS TTM Avg	-7.48%
Current VS 3Y Avg	-62.40%
Current VS 5Y Avg	-75.11%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	0.12%
FCF Yield Avg TTM	0.29%
FCF Yield Avg 3Y	0.34%
Current VS TTM Avg	-59.04%
Current VS 3Y Avg	-64.90%
Current VS 5Y Avg	-64.90%

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	384.95
Ev/Ebit Ratio Avg TTM	485.92
Ev/Ebit Ratio Avg 3Y	485.92
Current VS TTM Avg	-20.78%
Current VS 3Y Avg	-20.78%
Current VS 5Y Avg	-20.78%

Ev/Ebitda Ratio	86.99
Ev/Ebitda Ratio Avg TTM	109.81
Ev/Ebitda Ratio Avg 3Y	109.81
Current VS TTM Avg	-20.78%
Current VS 3Y Avg	-20.78%
Current VS 5Y Avg	-20.78%

Ev/Assets Ratio	21.70
Ev/Assets Ratio Avg TTM	14.44
Ev/Assets Ratio Avg 3Y	10.85
Current VS TTM Avg	+50.25%
Current VS 3Y Avg	+100.00%
Current VS 5Y Avg	+154.78%

Ev/Sales Ratio	21.30
Ev/Sales Ratio Avg TTM	13.63
Ev/Sales Ratio Avg 3Y	11.47
Current VS TTM Avg	+56.29%
Current VS 3Y Avg	+85.65%
Current VS 5Y Avg	+112.57%

Current Ratio	3.00
Current Ratio Avg TTM	3.27
Current Ratio Avg 3Y	3.78
Current VS TTM Avg	-8.26%
Current VS 3Y Avg	-20.73%
Current VS 5Y Avg	-20.46%

Quick Ratio	2.85
Quick Ratio Avg TTM	3.13
Quick Ratio Avg 3Y	3.64
Current VS TTM Avg	-8.72%
Current VS 3Y Avg	-21.63%
Current VS 5Y Avg	-21.43%

ROIC	(13.26%)
ROIC Avg 3Y	(24.44%)
ROIC Avg 5Y	(34.56%)
Current VS 3Y Avg	+45.75%
Current VS 5Y Avg	+61.63%
Current VS 10Y Avg	+68.47%

ROA	(7.24%)
ROA Avg TTM	(2.89%)
ROA Avg 3Y	(4.53%)
Current VS TTM Avg	-150.67%
Current VS 3Y Avg	-59.95%
Current VS 5Y Avg	-3.19%

ROE	(10.56%)
ROE Avg TTM	(16.10%)
ROE Avg 3Y	(32.57%)
Current VS TTM Avg	+34.40%
Current VS 3Y Avg	+67.58%
Current VS 5Y Avg	+81.48%

Net Profit Margin	(7.11%)
Net Profit Margin Avg TTM	(9.45%)
Net Profit Margin Avg 3Y	(13.87%)
Current VS TTM Avg	+24.78%
Current VS 3Y Avg	+48.74%
Current VS 5Y Avg	+81.28%

Gross Profit Margin	65.30%
Gross Pft Margin Avg TTM	64.96%
Gross Pft Margin Avg 3Y	60.41%
Current VS TTM Avg	+0.52%
Current VS 3Y Avg	+8.09%
Current VS 5Y Avg	+21.66%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A